INICSAFacultad de Ciencias Médicas (CONICET-FCM), Instituto de Fisiología, Córdoba, Argentina
Department of NeuroscienceFunctional Pharmacology, Uppsala University, Uppsala, Sweden.
Reproduction. 2018 Aug;156(2):121-132. doi: 10.1530/REP-17-0535. Epub 2018 May 23.
It has been demonstrated that food intake and reproductive physiology are both simultaneously modulated to optimize reproductive success under fluctuating metabolic conditions. Ghrelin (GHRL) is an orexigenic peptide identified as the endogenous ligand of the growth hormone secretagogue receptor that is being investigated for its potential role on reproduction. Considering that data available so far are still limited and characterization of GHRL action mechanism on the reproductive system has not been fully elucidated, we studied the participation of hypothalamus in GHRL effects on sperm functional activity, plasma levels of gonadotropins and histological morphology in mice testes after hypothalamic infusion of 0.3 or 3.0 nmol/day GHRL or artificial cerebrospinal fluid (ACSF) at different treatment periods. We found that GHRL 3.0 nmol/day administration for 42 days significantly reduced sperm concentration (GHRL 3.0 nmol/day = 14.05 ± 2.44 × 10/mL vs ACSF = 20.33 ± 1.35 × 10/mL, < 0.05) and motility (GHRL 3.0 nmol/day = 59.40 ± 4.20% vs ACSF = 75.80 ± 1.40%, < 0.05). In addition, histological studies showed a significant decrease percentage of spermatogonia (GHRL 3.0 nmol/day = 6.76 ± 0.68% vs ACSF = 9.56 ± 0.41%, < 0.05) and sperm (GHRL 3.0 nmol/day = 24.24 ± 1.92% vs ACSF = 31.20 ± 3.06%, < 0.05). These results were associated with a significant reduction in luteinizing hormone and testosterone plasma levels ( < 0.05). As GHRL is an orexigenic peptide, body weight and food intake were measured. Results showed that GHRL increases both parameters; however, the effect did not last beyond the first week of treatment. Results presented in this work confirm that central GHRL administration impairs spermatogenesis and suggest that this effect is mediated by inhibition of hypothalamic-pituitary-gonadal axis.
已经证明,在代谢条件波动的情况下,进食和生殖生理学同时受到调节,以优化生殖成功。Ghrelin(GHRL)是一种食欲肽,被确定为生长激素促分泌素受体的内源性配体,其在生殖方面的潜在作用正在研究中。考虑到到目前为止可用的数据仍然有限,并且 GHRL 对生殖系统作用机制的特征尚未完全阐明,我们研究了下丘脑在 GHRL 对精子功能活动、血浆促性腺激素水平和小鼠睾丸组织学形态的影响中的作用,方法是在不同的治疗期内,每天向下丘脑输注 0.3 或 3.0 nmol 的 GHRL 或人工脑脊液(ACSF)。我们发现,每天给予 3.0 nmol GHRL 42 天可显著降低精子浓度(GHRL 3.0 nmol/day=14.05±2.44×10^6/mL 与 ACSF=20.33±1.35×10^6/mL, < 0.05)和运动能力(GHRL 3.0 nmol/day=59.40±4.20%与 ACSF=75.80±1.40%, < 0.05)。此外,组织学研究表明,精原细胞(GHRL 3.0 nmol/day=6.76±0.68%与 ACSF=9.56±0.41%, < 0.05)和精子(GHRL 3.0 nmol/day=24.24±1.92%与 ACSF=31.20±3.06%, < 0.05)的百分比显著降低。这些结果与黄体生成素和睾酮血浆水平的显著降低相关( < 0.05)。由于 GHRL 是一种食欲肽,因此测量了体重和食物摄入量。结果表明,GHRL 增加了这两个参数;然而,这种作用在治疗的第一周后就不再持续。本工作中提出的结果证实,中枢给予 GHRL 会损害精子发生,并表明这种作用是通过抑制下丘脑-垂体-性腺轴介导的。